US FDA gives green light for WuXi intermediate manufacturing

By Dan Stanton

- Last updated on GMT

US FDA gives green light for WuXi intermediate manufacturing
US FDA gives green light for WuXi intermediate manufacturing
The US FDA has completed a pre-approval inspection at a Wuxi PharmaTech facility in order for the firm to manufacture a new intermediate for a client.

The regulatory body “found no issues requiring a Form 483”​ at a facility in Jinshan, near Shanghai, belonging to WuXi's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Company (STA), according to Director of Investor Relations Ron Aldridge.

Aldridge told Outsourcing-pharma.com the inspection was necessary as the facility is “now manufacturing an intermediate that required regulatory review”​ though, due to client confidentially, he was unable to divulge either the client or the product.

“The commercial products we have manufactured to date have been advanced intermediates that did not require FDA inspection,”​ he said, adding the site - which has been commercial manufacturing small molecule APIs and advanced intermediates since 2010 - would be boosted by this regulatory thumbs up.

On top of ingredients for marketed products, the facility produces study materials for preclinical and clinical trial. All are intended for the global market, Aldridge said, with STA’s customers being mainly multinational pharmaceutical companies.

WuXi has not been involved in any quality or regulatory issues, according to Aldridge, and the site in Jinshan is cGMP quality.

“This FDA inspection shows that we meet the highest regulatory standards,” ​he said. “The uptake from U.S. and European customers has been very strong, as evidenced in the seven-fold increase in our manufacturing revenues between 2009 and 2013.

We expect continued strong growth in manufacturing revenue as a result of the strong pipeline of projects and large customer base we have built.”

Related news

Show more

Related products

show more

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars